A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases.
Jeising S, Nickel AC, Trübel J, Felsberg J, Picard D, Leprivier G, Wolter M, Huynh MK, Olivera MB, Kaulich K, Häberle L, Esposito I, Klau GW, Steinmann J, Beez T, Rapp M, Sabel M, Dietrich S, Remke M, Cornelius JF, Reifenberger G, Qin N.
Jeising S, et al. Among authors: nickel ac.
J Neurooncol. 2024 Sep;169(3):613-623. doi: 10.1007/s11060-024-04763-7. Epub 2024 Jul 10.
J Neurooncol. 2024.
PMID: 38985431
Free PMC article.